Yahoo Finance Stoke Therapeutics Gets JPMorgan Upgrade
By Sam Boughedda
Investing.com — Stoke Therapeutics Inc (NASDAQ:STOK) shares rose 13% after it was given a bullish rating from JPMorgan analyst Jessica Fye.
Stoke was upgraded to overweight from neutral, with a price target of $41.
The analyst told investors that she likes the company's proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO), "as a driver of long-term value creation."
Fye also said she sees reason for efficacy with Stoke's lead therapeutic candidate, STK-001, a therapy for treating Dravet Syndrome, a rare form of epilepsy.
STK-001 is currently in a Phase 1/2 study with efficacy and safety data expected in the fourth quarter and the second half of 2022.
"We see near-term upside driven by ‘001 (and limited downside) and a solid technology platform that could continue to generate shareholder value through follow-on assets over the next 12 months," explained Fye.
Related Articles
Stoke Therapeutics Gets JPMorgan Upgrade
American Airlines, JetBlue ask court to throw out U.S. antitrust suit
GM Acquires Stake in All-Electric Boating Business Pure Watercraft
